Prot #KCP-330-008: A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients = 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are

Project: Research project

Project Details

StatusFinished
Effective start/end date5/14/145/14/20

Funding

  • Karyopharm Therapeutics Inc. (Prot #KCP-330-008)